Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ebs · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Emergent BioSolutions Inc. (EBS) measures how much investors pay for each dollar of the company's trailing earnings. EBS's current PE ratio of N/A is calculated by dividing its stock price of $8.22 by its TTM earnings per share of -$0.17.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%24.6x
MedianQ3 · 75%51.0x
Max
At N/A, EBS's current P/E is lower than in 0% of its annual fiscal year readings over the past 17 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Emergent BioSolutions Inc.You EBS | $424M | N/A | — | -$0.17 |
 Aquestive Therapeutics, Inc. AQST | $387M | N/A | — | -$0.69 |
 COMPASS Pathways plc CMPS | $1.1B | N/A | — | -$3.08 |
 Corvus Pharmaceuticals, Inc. CRVS | $940M | N/A | — | -$0.19 |
 Esperion Therapeutics, Inc. ESPR | $655M | N/A | — | -$0.11 |
 Olema Pharmaceuticals, Inc. OLMA | $878M | N/A | — | -$1.87 |
 Organogenesis Holdings Inc. ORGO | $309M | 17.73x | — | $0.29 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 12.57x | $0.98 | — | |
2024-12-31 FY2024 | — | $-3.60 | — | |
2023-12-31 FY2023 | — | $-14.85 | — | |
2022-12-31 FY2022 | — | $-4.22 | — | |
2021-12-31 FY2021 | 10.60x | $4.10 | -31.4% | |
2020-12-31 FY2020 | 15.44x | $5.80 | -69.7% | |
2019-12-31 FY2019 | 50.98x | $1.06 | +7.6% | |
2018-12-31 FY2018 | 47.37x | $1.25 | +101.3% | |
2017-12-31 FY2017 | 23.53x | $1.98 | -7.7% | |
2016-12-31 FY2016 | 25.48x | $1.29 | +3.7% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Emergent BioSolutions Inc. (EBS) measures how much investors pay for each dollar of the company's trailing earnings. EBS's current PE ratio of N/A is calculated by dividing its stock price of $8.22 by its TTM earnings per share of -$0.17.
Frequently asked questions
EBS pe ratio · 6 questionsEBS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.22 and TTM EPS of -$0.17. Data sourced from Financial Modeling Prep via EBS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Emergent BioSolutions Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08